×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KRYS – krystal biotech, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KRYS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/23
06:50 am
krys
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? [Yahoo! Finance]
Low
Report
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? [Yahoo! Finance]
12/18
01:19 pm
krys
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $212.00 price target on the stock.
Medium
Report
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $212.00 price target on the stock.
12/18
08:14 am
krys
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer [Yahoo! Finance]
High
Report
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer [Yahoo! Finance]
12/18
08:07 am
krys
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.
Medium
Report
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.
12/18
08:00 am
krys
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
Medium
Report
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
12/12
01:07 pm
krys
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $212.00 price target on the stock.
Low
Report
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $212.00 price target on the stock.
12/12
08:00 am
krys
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels
Medium
Report
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels
12/10
08:00 am
krys
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.
Medium
Report
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/18
08:40 am
krys
Form 8-K Krystal Biotech, Inc. For: Dec 18
High
Report
Form 8-K Krystal Biotech, Inc. For: Dec 18
12/13
06:29 pm
krys
Form 4 Krystal Biotech, Inc. For: Dec 13 Filed by: Krishnan Suma
Low
Report
Form 4 Krystal Biotech, Inc. For: Dec 13 Filed by: Krishnan Suma
12/13
06:28 pm
krys
Form 4 Krystal Biotech, Inc. For: Dec 13 Filed by: Krishnan Krish S
Low
Report
Form 4 Krystal Biotech, Inc. For: Dec 13 Filed by: Krishnan Krish S
12/13
04:22 pm
krys
Form 144 Krystal Biotech, Inc. Filed by: Krishnan Suma
Low
Report
Form 144 Krystal Biotech, Inc. Filed by: Krishnan Suma
12/13
04:22 pm
krys
Form 144 Krystal Biotech, Inc. Filed by: Krishnan Krish S
Low
Report
Form 144 Krystal Biotech, Inc. Filed by: Krishnan Krish S
12/12
08:31 am
krys
Form 8-K Krystal Biotech, Inc. For: Dec 12
Medium
Report
Form 8-K Krystal Biotech, Inc. For: Dec 12
11/14
09:01 pm
krys
Form SC 13G/A Krystal Biotech, Inc. Filed by: Redmile Group, LLC
Low
Report
Form SC 13G/A Krystal Biotech, Inc. Filed by: Redmile Group, LLC
11/12
10:33 am
krys
Form SC 13G/A Krystal Biotech, Inc. Filed by: FMR LLC
Medium
Report
Form SC 13G/A Krystal Biotech, Inc. Filed by: FMR LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/24
Form 8-K Krystal Biotech, Inc. For: Jun 24
41.3%
3/18 Form 4 Krystal Biotech, Inc. For: Mar 16 Filed by: Krishnan Suma 12.1%
7/1 Krystal Biotech, Inc. Added to the Russell 2000 Index 9.5%
3/10 Krystal Biotech Inc (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock. 9.1%
6/27 Form 8-K Krystal Biotech, Inc. For: Jun 24 8.1%
11/4 Krystal Biotech Inc (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at William Blair. 7.5%
4/13 Form DEF 14A Krystal Biotech, Inc. For: May 29 7.3%
11/21 Form 4 Krystal Biotech, Inc. For: Nov 19 Filed by: Riley Antony A 6.3%
11/27 Krystal Biotech Inc (NASDAQ: KRYS) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 5.9%
8/27 Krystal Biotech Announces Attendance at Citi’s 14th Annual Biotech Conference 5.8%
3/18 Form 4 Krystal Biotech, Inc. For: Mar 16 Filed by: Krishnan Suma 12.1%
7/1 Krystal Biotech, Inc. Added to the Russell 2000 Index 9.5%
3/10 Krystal Biotech Inc (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock. 9.1%
6/27 Form 8-K Krystal Biotech, Inc. For: Jun 24 8.1%
11/4 Krystal Biotech Inc (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at William Blair. 7.5%
4/13 Form DEF 14A Krystal Biotech, Inc. For: May 29 7.3%
11/21 Form 4 Krystal Biotech, Inc. For: Nov 19 Filed by: Riley Antony A 6.3%
11/27 Krystal Biotech Inc (NASDAQ: KRYS) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 5.9%
8/27 Krystal Biotech Announces Attendance at Citi’s 14th Annual Biotech Conference 5.8%
TOP News Decliners
9/27
Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent
-13.6%
6/14 Krystal Submits Investigational New Drug (IND) Application for KB105, Topical Gene Therapy Candidate for Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis -11.2%
9/24 Krystal Biotech Inc (NASDAQ: KRYS) is now covered by analysts at Goldman Sachs Group Inc. They set a "neutral" rating on the stock. -11.0%
12/18 Form 4 Krystal Biotech, Inc. For: Dec 16 Filed by: Krishnan Suma -10.8%
2/25 Krystal Biotech Announces Change in Financial Leadership -8.0%
8/2 Krystal Biotech Inc (NASDAQ: KRYS) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -7.0%
7/23 Krystal Biotech Inc (NASDAQ: KRYS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock. -6.9%
2/18 Form SC 13G Krystal Biotech, Inc. Filed by: ORBIMED ADVISORS LLC -5.3%
6/25 Krystal Biotech Inc (NASDAQ: KRYS) had its price target raised by analysts at Guggenheim from $48.00 to $73.00. They now have a "buy" rating on the stock. -5.2%
9/30 Krystal Biotech Inc (NASDAQ: KRYS) was given a new $81.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock. -4.5%
6/14 Krystal Submits Investigational New Drug (IND) Application for KB105, Topical Gene Therapy Candidate for Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis -11.2%
9/24 Krystal Biotech Inc (NASDAQ: KRYS) is now covered by analysts at Goldman Sachs Group Inc. They set a "neutral" rating on the stock. -11.0%
12/18 Form 4 Krystal Biotech, Inc. For: Dec 16 Filed by: Krishnan Suma -10.8%
2/25 Krystal Biotech Announces Change in Financial Leadership -8.0%
8/2 Krystal Biotech Inc (NASDAQ: KRYS) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -7.0%
7/23 Krystal Biotech Inc (NASDAQ: KRYS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock. -6.9%
2/18 Form SC 13G Krystal Biotech, Inc. Filed by: ORBIMED ADVISORS LLC -5.3%
6/25 Krystal Biotech Inc (NASDAQ: KRYS) had its price target raised by analysts at Guggenheim from $48.00 to $73.00. They now have a "buy" rating on the stock. -5.2%
9/30 Krystal Biotech Inc (NASDAQ: KRYS) was given a new $81.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock. -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: